Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people.
Crohn's Disease Research Studies
Investigators
Open Research Studies for Crohn's Disease
Diversity
Enrolling: Yes
Principle Investigator: Matthew Bohm, MD
Duration: 32-66 weeks + Long-term Extension (Approx. 8-13 clinic visits)
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Filgotinib (Oral)
Possibility of Placebo: 1 in 3
Galaxi
Enrolling: Yes
Principle Investigator: Sashidhar Sagi, MD
Duration: 48 weeks + potential to receive up to 2 additional years of treatment
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Guselkumab or Ustekinumab ( IV + Subcutaneous)
Possibility of Placebo: 1 in 5
Yellowstone
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: 12 Weeks + potential to receive treatment for up to 4.5 years
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Ozanimod (Oral)
Possibility of Placebo: 1 in 3
SPARC IBD
Enrolling: Yes
Principle Investigator: Matthew Bohm, DO
Duration: All bio-specimen collections and chart reviews will continue until 2026
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Intervention: Medical chart reviews and biological specimen collection.
VIVID - 1
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: 1 year – Option to roll into the long term extension study VIVID-2
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: Mirikizumab vs Stelara vs Placebo
Possibility of Placebo: 2 in 11
IBD QORUS
Enrolling: Yes
Principle Investigator: Sashidhar Sagi, MD
Duration: Indefinate or upon withdraw
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Procedures: Patient surveys before every office visit & medical chart reviews
Lattice
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: Approximately 112 weeks
Patient Population: Adult patients with moderately to severely active Crohn’s disease
Study Intervention: BMS-986165 (oral)
Possibility of Placebo: 1 in 4